Jeffrey Weber, MD, PhD, Describes Unmet Needs for Patients with Melanoma

Video
Conference|International Congress of the Society for Melanoma Research (SMR)

Jeffrey Weber, MD, PhD, discusses the unmet needs professionals take into consideration when deciding treatment options for patients with melanoma.

Jeffrey Weber, MD, PhD, of NYU Langone Health spoke with CancerNetwork regarding the unmet needs for patients with melanoma and the binary treatment options for this group of patients.

Transcription:

So, the challenge in our business is which treatment to give them after surgery, what adjuvant treatment? It comes down to a particular binary choice, we either give them PD-1 antibodies like nivolumab (Opdivo) or pembrolizumab (Keytruda) or you give them BRAF/MEK drugs and dabrafenib/trametinib are the 2 approved for that indication. So, the unmet need is what do you do after surgery for a high-risk patient? The other unmet need is what do you do in metastatic disease? And there, it comes down to what’s your front-line treatment, and generally that’s immunotherapy. Then the question is, if you’re BRAF-mutated, what do you do if you fail immunotherapy? If you fail (ipilimumab [Yervoy] plus nivolumab), you don’t have a lot of options. So, that’s where BRAF/MEK drugs will come in handy and have been very useful.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Related Content
Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.

Data Show Barriers to Immunotherapy Access in Clear Cell RCC Population

December 1st 2023
Article

Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD.

Durvalumab/Tremelimumab/Surgery Appears Safe in Renal Cell Carcinoma

November 30th 2023
Article

Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD, PhD.

Experts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.

Oncology On-The-Go Podcast: SGO 2023 Recap

April 24th 2023
Podcast

Experts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.

Investigators report a trend in overall survival improvement among patients with advanced/recurrent endometrial cancer treated with atezolizumab and chemotherapy.

Atezolizumab/Chemo Provides PFS Benefit in Advanced Endometrial Cancer

November 21st 2023
Article

Investigators report a trend in overall survival improvement among patients with advanced/recurrent endometrial cancer treated with atezolizumab and chemotherapy.

Data from the phase 2 DESTINY-PanTumor02 trial support trastuzumab deruxtecan as a potential treatment for patients with gynecologic HER2-expressing tumors that have progressed on prior therapy.

Trastuzumab Deruxtecan Showcases Clinical Efficacy in HER2+ Gynecological Cancers

November 20th 2023
Article

Data from the phase 2 DESTINY-PanTumor02 trial support trastuzumab deruxtecan as a potential treatment for patients with gynecologic HER2-expressing tumors that have progressed on prior therapy.